Safety monitoring finds 97% nonserious reactions to Janssen COVID-19 vaccine, detects 17 thrombotic events

A safety monitoring report analyzed data from individuals in the United States who received the Janssen (Johnson & Johnson) COVID-19 vaccine, representing nearly 8 million administered doses. The report did not specify a comparator group, follow-up duration, or primary outcome measures. The main finding was that 97% of reported reactions following vaccination were classified as nonserious. Seventeen cases of thrombotic events with thrombocytopenia were detected through surveillance, which included three events not classified as cerebral venous sinus thrombosis (CVST). No specific data on other adverse events, serious adverse events beyond the thrombotic cases, tolerability, or discontinuation rates were reported. The report did not provide absolute numbers for reactions, effect sizes, confidence intervals, or p-values for the findings. Key limitations of the evidence were not explicitly reported, including potential under-reporting, lack of a control group for risk calculation, and the observational nature of passive surveillance data. The practice relevance was not specified, and no causality assessment between the vaccine and the thrombotic events was provided in the input. These findings represent early safety signals from post-authorization monitoring that clinicians should be aware of, but they do not establish comparative risk or definitive causal relationships.